Evidence map›Paper›PMID 38615030›Full record

ArticleNPJ Parkinson's disease2024

GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults.

Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard J Smeyne, Adam E Snook, Scott A Waldman

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Immunotherapy for precision medicine in colorectal cancer.Expert review of precision medicine and drug development · 2025
    Article
  3. Article
  4. Article
  5. Antioxidant and Neuroprotective Effects of Seed Oils fromAntioxidants (Basel, Switzerland) · 2024
    Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Lara CheslowDepartment of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0880-5957
Matthew ByrneDepartment of Neurosciences, Thomas Jefferson University, Philadelphia, PA, USA.
Jessica S KopenhaverDepartment of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Lorraine IacovittiDepartment of Neurosciences, Thomas Jefferson University, Philadelphia, PA, USA.
Richard J SmeyneDepartment of Neurosciences, Thomas Jefferson University, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8459-5472
Adam E SnookDepartment of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-9216-4560
Scott A WaldmanDepartment of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA. scott.waldman@jefferson.edu.ORCID http://orcid.org/0000-0001-6619-175X

Funding

(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformationR01CA206026 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2016 to 2020
$1.8M
Neuroprotection by the GUCY2C gut-brain axis in Parkinson's diseaseR21NS130388 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2023 to 2023
$429k
Off-the-shelf CAR-T Therapy via Tumor-Selective Immuno-engagersR21CA267087 · NCI · LEHIGH UNIVERSITY · PI SNOOK, ADAM, THEVENIN, DAMIEN · 2022 to 2023
$402k
Parkinson's disease therapies targeting GUCY2CF30NS125921 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI CHESLOW, LARA · 2022 to 2025
$179k
NCI NIH HHS R01 CA206026NCI NIH HHS R21 CA267087NINDS NIH HHS F30 NS125921NINDS NIH HHS R21 NS130388
6 · The paper itself

Abstract

Mitochondrial dysfunction and reactive oxygen species (ROS) accumulation within the substantia nigra pars compacta (SNpc) are central drivers of dopaminergic (DA) neuron death in Parkinson's disease (PD). Guanylyl cyclases and their second messenger cyclic (c)GMP support mitochondrial function, protecting against ROS and promoting cell survival in several tissues. However, the role of the guanylyl cyclase-cGMP axis in defining the vulnerability of DA neurons in the SNpc in PD remains unclear, in part due to the challenge of manipulating cGMP levels selectively in midbrain DA neurons. In that context, guanylyl cyclase C (GUCY2C), a receptor primarily expressed by intestinal epithelial cells, was discovered recently in midbrain DA neurons. Here, we demonstrate that GUCY2C promotes mitochondrial function, reducing oxidative stress and protecting DA neurons from degeneration in the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) mouse model. GUCY2C is overexpressed in the SNpc in PD patients and in mice treated with MPTP, possibly reflecting a protective response to oxidative stress. Moreover, cGMP signaling protects against oxidative stress, mitochondrial impairment, and cell death in cultured DA neurons. These observations reveal a previously unexpected role for the GUCY2C-cGMP signaling axis in controlling mitochondrial dysfunction and toxicity in SNpc DA neurons, highlighting the therapeutic potential of targeting DA neuron GUCY2C to prevent neurodegeneration in PD.

Identifiers

PMID38615030
PMCPMC11016112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.